CollPlant Biotechnologies operates in regenerative and aesthetic medicine with a core platform built on recombinant human collagen produced via plant-based genetic engineering. This approach provides a scalable and consistent alternative to traditional animal- or human-derived sources, which I see as a key differentiator in the space.
The company targets three main areas. Its partnership with AbbVie (via Allergan) in medical aesthetics ties the platform to a major player in dermal fillers, with potential milestone payments and royalties ahead. In regenerative medicine, 3D-bioprinted breast implants and a photocurable dermal filler aim at reconstructive and aesthetic uses. The Collink.3D bioinks support tissue engineering and drug discovery, aligning with trends away from animal testing.
As a micro-cap firm still early in commercialization, CLGN has limited recurring revenue and ongoing losses. Its outlook hinges on advancing pipeline milestones and partner outcomes. Intellectual property protection, with patents extending into the late 2030s in key markets, adds a layer of competitive strength.
Several events stand out as potential valuation drivers for CLGN. AbbVie's review of interim data from the dermal-filler trials initiated in 2023 is the most immediate, since AbbVie decides on further development steps.
Progress on the internally developed photocurable dermal filler, now moving past preclinical work toward scale-up and an IND filing, offers another independent milestone. In regenerative medicine, ongoing work on 3D-bioprinted breast implants could provide longer-term validation if clinical translation advances.
Near-term capital markets items include the planned 1-for-10 reverse stock split and efforts to meet Nasdaq bid-price requirements. Analyst views remain scattered, with limited coverage and targets spanning hold, buy, and reduce ratings.
CollPlant's path intersects with broader trends. Aesthetic filler demand can fluctuate with consumer spending, which may soften under persistent inflation or higher rates. A selective market could still reward differentiated products like the photocurable filler once it advances.
Regulatory support for non-animal testing methods from the FDA represents a potential tailwind for the bioinks portfolio. On the other side, a higher-for-longer rate environment raises financing costs for pre-revenue biotechs, which explains the November 2025 restructuring. Regional factors tied to the company's Israel base can also affect sentiment from time to time.
When evaluating momentum alongside the fundamental catalysts, I also checked this using Tickeron’s AI Screener to see how CLGN compares within its peer group. This helps frame the technical picture without replacing core analysis of milestones and partnerships.
Looking ahead, partnership execution with AbbVie will likely set the tone for revenue conversion through milestones and royalties. Clinical advancement of the photocurable filler and breast implant programs will test the platform in large markets, while the cost reductions aim to preserve runway until those programs mature.
Listing compliance and future capital decisions remain priorities. With dispersed external views on valuation, CLGN's narrative in 2026 will center on milestone delivery rather than near-term financial metrics.
I have found Tickeron's Trend Prediction Engine to be a practical addition to my routine when assessing whether a stock like CLGN may lean bullish, bearish, or sideways over the near term. It surfaces searchable forecasts, historical context, and alerts that complement fundamental reviews of catalysts and industry dynamics, helping me cross-check momentum signals before forming a fuller view.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
CLGN saw its Momentum Indicator move above the 0 level on October 29, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 73 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 83%.
CLGN moved above its 50-day moving average on November 12, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for CLGN crossed bullishly above the 50-day moving average on November 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +19.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLGN advanced for three days, in 168 of 207 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 59 of 81 cases where CLGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The 50-day moving average for CLGN moved below the 200-day moving average on November 11, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CLGN broke above its upper Bollinger Band on November 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.560) is normal, around the industry mean (3.586). P/E Ratio (-3.875) is within average values for comparable stocks, (-1.188). Projected Growth (PEG Ratio) (0.290) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.494) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. CLGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of medical devices
Industry Biotechnology